Skip to main content

Table 3 Hazard ratios for invasive ductal carcinomas, invasive lobular carcinomas, and ductal carcinomas in situ

From: Long-term use of calcium channel blocking drugs and breast cancer risk in a prospective cohort of US and Puerto Rican women

 

Invasive ductal carcinoma

(1009 cases)

Invasive lobular carcinoma

(130 cases)

Ductal carcinoma in situ

(459 cases)

Calcium channel blockers

Never used

Reference

Reference

Reference

Former user

1.05 (0.59–1.86)

1.68 (0.41–6.85)

0.98 (0.41–2.38)

Current user (<5 years)

0.66 (0.45–0.97)

2.26 (1.12–4.55)

0.78 (0.46–1.35)

 (5–10 years)

1.05 (0.66–1.66)

1.13 (0.28–4.61)

1.28 (0.68–2.41)

 (10+ years)

0.80 (0.45–1.42)

0.69 (0.10–4.99)

0.80 (0.33–1.94)

All antihypertensives

Never used

Reference

Reference

Reference

Former user

1.03 (0.69–1.53)

0.30 (0.04–2.16)

1.15 (0.66–2.01)

Current user (<5 years)

0.90 (0.74–1.08)

0.88 (0.51–1.50)

1.06 (0.82–1.39)

 (5–10 years)

0.97 (0.77–1.22)

1.21 (0.65–2.24)

0.87 (0.60–1.26)

 (10+ years)

0.94 (0.74–1.19)

0.57 (0.24–1.34)

0.88 (0.60–1.28)

  1. Data presented as hazard ratio (95 % confidence interval)
  2. Hazard ratios were calculated using Cox proportional hazards regression with age as the time scale and adjusted for race/ethnicity, categorized body mass index, parity, age at menarche, menopause status, statin use, smoking status, hormone therapy use, and reported hours of physical activity per week